DYN Insider Trading Activity and SEC Form 4 Filings
DYN insider trading summary
Over the past 12 months, insiders at Dyne Therapeutics, Inc. (DYN) reported 95 sales worth $139.8M by 6 insiders and 6 open-market purchases worth $232K by 1 insider on SEC Form 4. Net insider selling was $139.6M.
Latest DYN insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 2, 2026 | Brian S Posner | Insider | Buy | $40K (2,500 @ $16.00) |
| Sep 8, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sell | $3K (185 @ $18.88) |
| Sep 8, 2026 | Douglas Kerr | Chief Medical Officer | Sell | $24K (1,290 @ $18.88) |
| Sep 8, 2026 | John Cox | CEO & President | Sell | $107K (5,658 @ $18.88) |
| Sep 4, 2026 | Johanna Friedl-Naderer | Chief Commercial Officer | Sell | $22K (900 @ $24.35) |
| Sep 4, 2026 | Douglas Kerr | Chief Medical Officer | Sell | $91K (3,745 @ $24.35) |
| Aug 14, 2026 | Jason P Rhodes | Insider | Sell | $34.0M (1,359,674 @ $25.00) |
| Aug 14, 2026 | Jason P Rhodes | Insider | Sell | $12.0M (478,377 @ $25.00) |
| Aug 14, 2026 | Jason P Rhodes | Insider | Sell | $8.1M (322,465 @ $25.00) |
| Aug 13, 2026 | John Cox | CEO & President | Sell | $131K (4,986 @ $26.28) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.